Anatomy Of A Biotech Company: Acorda Gets Dressed For A Second Act

Acorda's rise, fall, and attempt to rise again is a snapshot of the life of a biotech. The company reached the commercial-stage pinnacle with Ampyra, only to eventually see it fall away to patent challenges. Now, after big staff cuts, the company is hoping to prevail in the commercial market again, this time with Inbrija.

Acorda Headquarters in Ardly NY

Two years ago, Acorda Therapeutics Inc. CEO Ron Cohen was sitting in the witness chair in the US District Court for the District of Delaware, trying to convince US District Judge Leonard Stark that the company's lead product Ampyra (dalfampridine) was a novel invention worthy of its patent protection.

Flash forward to today and the company has been through quite a re-invention. Acorda lost the patent infringement case and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Leadership

More from Scrip